血清铁蛋白与透析患者死亡率的关联:来自美国、日本和欧洲DOPPS研究的发现
结果显示,三个地区高铁蛋白水平均与死亡率升高相关,且营养不良和炎症的调整对关联强度的削弱作用大于静脉铁剂和促红细胞生成素剂量。结论提示高铁蛋白作为铁过载风险生物标志物的效用可能有限。
要点
- 高铁蛋白水平与美国、欧洲和日本透析患者的1年死亡率升高相关。
- 营养不良和炎症对铁蛋白-死亡率关联的混杂影响大于静脉铁剂和ESA剂量。
- 高铁蛋白作为铁过载风险标志物的临床效用可能有限,但高目标铁蛋白上限的静脉铁剂仍应谨慎。
核心结论
- 高铁蛋白与透析患者死亡率升高相关,但该关联更多由营养不良和炎症解释,而非静脉铁剂或ESA剂量。
- 高铁蛋白作为铁过载风险生物标志物的效用可能有限,对高上限铁蛋白目标的静脉铁剂补铁仍需谨慎。
研究设计与样本
- 采用Cox回归模型和限制性立方样条分析基线铁蛋白与1年死亡率的关联。
主要发现
- 中位铁蛋白水平:美国718 ng/mL,欧洲405 ng/mL,日本83 ng/mL。
- 相对于地区特异性中位数,高铁蛋白水平在三个地区均与死亡率升高相关。
- 调整营养不良和炎症后,铁蛋白-死亡率关联强度的减弱程度大于调整静脉铁剂和ESA剂量。
临床怎么用
- 临床解读高铁蛋白时需考虑营养不良和炎症的混杂影响,不宜仅凭铁蛋白水平评估铁过载风险。
- 对高铁蛋白目标上限的静脉铁剂补铁仍应保持谨慎。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 铁蛋白与死亡率关联的因果性无法确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Kidney Disease: Improving Global Outcomes guidelines have cautioned against administering intravenous (IV) iron to hemodialysis patients with high serum ferritin levels due to safety concerns, but prior research has shown that the association between high ferritin and mortality could be attributed to confounding by malnutrition and inflammation. Our goal was to better understand the ferritin-mortality association and relative influence of IV iron and inflammation in the USA, where ferritin levels have recently increased dramatically, and in Europe and Japan, where ferritin levels are lower and anemia management practices differ. METHODS: Data from 18 261 patients in Phases 4 and 5 (2009-15) of the international Dialysis Outcomes and Practice Patterns Study, a prospective cohort study, were analyzed. Using Cox regression, we modeled the association between baseline ferritin and 1-year mortality with restricted cubic splines and assessed the impact of potential confounders. RESULTS: Median ferritin levels were 718 ng/mL in the USA, 405 in Europe and 83 in Japan. High ferritin levels were associated with elevated mortality (relative to region-specific medians) in all three regions. The strength of this association was attenuated more by adjustment for malnutrition and inflammation than by IV iron and erythropoiesis-stimulating agent dose in each region. CONCLUSION: The utility of high ferritin as a biomarker for clinical risk due to excess iron stores may be limited, although caution regarding IV iron dosing to higher upper ferritin targets remains warranted. Research to resolve biomarker criteria for iron dosing, and whether optimal anemia management strategies differ internationally, is still needed.
引用
- Karaboyas A, Morgenstern H, Pisoni RL, et al. Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2018. PMID: 30010940. doi:10.1093/ndt/gfy190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。